USA-based Abbott Laboratories (NYSE ABT) announced strong initial results from “Aviator," a Phase IIb study of its interferon-free, investigational regimen for the treatment of hepatitis C (HCV), reporting near complete cure rates in the trial.
Initial results show sustained virological response at 12 weeks post treatment (SVR12) in 99% of treatment-naïve (n=77) and 93% of null responders (n=41) for genotype 1 (GT1) HCV patients taking a combination of ABT-450/r, ABT-267, ABT-333 and ribavirin for 12 weeks, based on an observed data analysis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze